115 related articles for article (PubMed ID: 21487718)
1. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Horak J; White J; Harris AL; Verrill M; Carmichael J; Holt A; Cantarini M; Macpherson M; Swaisland A; Swaisland H; Twelves C
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1485-95. PubMed ID: 21487718
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
van Herpen CM; Lassen U; Desar IM; Brown KH; Marotti M; de Jonge MJ
Anticancer Drugs; 2013 Feb; 24(2):204-11. PubMed ID: 23197081
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
4. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
5. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
7. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
Abbas R; Chalon S; Leister C; El Gaaloul M; Sonnichsen D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):123-32. PubMed ID: 23053269
[TBL] [Abstract][Full Text] [Related]
11. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
14. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment.
Li Z; Gan LS; Marbury T; Lasseter KC; Natarajan A; Stecher S; Wei D; Yang L; Freedman D; Deykin A
J Clin Pharmacol; 2012 Apr; 52(4):543-51. PubMed ID: 21610206
[TBL] [Abstract][Full Text] [Related]
16. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
[TBL] [Abstract][Full Text] [Related]
17. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
Horsmans Y; Hu K; Ruffin M; Wang Y; Song D; Bouillaud E; Wang Y; Mazur D; Botha FP; Heuman DM
J Clin Pharmacol; 2012 Apr; 52(4):552-8. PubMed ID: 22282526
[TBL] [Abstract][Full Text] [Related]
18. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Brockmöller J; Thomsen T; Wittstock M; Coupez R; Lochs H; Roots I
Clin Pharmacol Ther; 2005 Jun; 77(6):529-41. PubMed ID: 15961984
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
